Markus Weiss

🚀 Formycon AG Expands FYB203 (Aflibercept Biosimilar) Access in Europe Formycon has announced a new licensing agreement between Klinge Biopharma and Horus Pharma, granting Horus the rights to commercialize FYB203 (marketed as Baiama) in select European countries, including France. This deal complements the earlier partnership with Teva Pharmaceuticals, which is launching FYB203 as Ahzantive. 🔗 Read more here: https://lnkd.in/dPH3uTNK #Collaboration #Launch #AMD #EyeHealth #CompanyNews #Ophthalmology #Biosimilars #Formycon #FYB203 #Teva #HorusPharma

52

We are proud to announce Omega Pharma's acquisition of Cieffe Derma, an Italian company specialized in the development and commercialization of scientifically-supported products with a particular focus on dermatology. This acquisition represents Omega’s second add-on in the nutraceutical sector since joining 21 Invest’s portfolio in February 2024, following the acquisition of Inpha in December 2024. Thanks to the acquisition of Cieffe Derma, Omega Pharma aims to exceed €M 40 in revenue in 2025, with a network of around 200 scientific representatives operating throughout Italy. Andrea Mazzucato, Stefano De Rossi, Massimo Galli, Valentina Mattiussi Omega Pharma SRL, Cieffe Derma

123

1 Kommentar

Could Basel be the next Boston❓   When you think of biotech powerhouses, Boston or the Bay Area may come to mind. But the Basel Area in Switzerland is making a strong case to join that list.   Anchored by Roche and Novartis, the region now counts 800+ life sciences companies from global players like BeOne Medicines, Lonza, Basilea Pharmaceutica, Syngenta Group to startups pushing the frontiers of diagnostics, therapeutics, and manufacturing.   In this article, Fierce Biotech explores how the Basel Area is quietly but powerfully raising its game and how its Switzerland Innovation Park Basel Area is right at the heart of the story.   📰Read the full article: https://lnkd.in/g_XYQbWj #WhySwitzerland #LifeSciences Switzerland Innovation Swissnex swisstech Presence Switzerland Basel Area Business & Innovation Swiss Biotech Association Christof Kloepper Maximilien Murone Teresa Harris Graham David Veitch Adesh Kaul University of Basel Alentis Therapeutics Bright Peak Therapeutics Swiss Tropical and Public Health Institute Innosuisse Deep Tech Nation Switzerland SixPeaks Bio

600

18 Kommentare

𝗛𝗼𝘄 𝗱𝗼 𝗕𝗲𝗿𝗹𝗶𝗻’𝘀 𝘀𝘁𝗮𝗿𝘁-𝘂𝗽𝘀 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀? 𝗛𝗲𝗮𝗿 𝗳𝗿𝗼𝗺 𝗖𝗵𝗮𝗿𝗹𝗼𝘁𝘁𝗲 𝗞𝗼𝗽𝗶𝘁𝘇 𝗮𝘀 𝘀𝗵𝗲 𝘀𝗵𝗮𝗿𝗲𝘀 𝗵𝗼𝘄 𝗡𝘂𝘃𝗶𝘀𝗮𝗻’𝘀 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗻𝗱 𝗴𝗹𝗼𝗯𝗮𝗹 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝗮𝗿𝗲 𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝗕𝗲𝗿𝗹𝗶𝗻 Charlotte Kopitz, Head of Discovery Research Nuvisan & General Manager CRO Discovery ALS Pharma, was recently interviewed by HealthCapital Berlin-Brandenburg about how we drive innovation for Berlin start-ups. She discussed Berlin’s unique life science ecosystem, how Nuvisan empowers early-stage companies through initiatives like our Drug Discovery Innovation Challenge, and the new global opportunities opened up by our integration into the ALS Group. Read the full interview to discover how we partner with our clients to bring therapeutics to life at https://lnkd.in/d_yAs3ma #innovation #partnership #Berlin #Nuvisan #theScienceCRO

125

3 Kommentare

As SFC Europe 2025 is in full swing in Basel, LCGC International spoke to John Reilly, Maria Kristina Parr, and Larry Miller about the important role that SFC now plays in life science analysis. Read the interview here: https://lnkd.in/gHh8X4xM

144

5 Kommentare

𝗢𝗽𝗲𝗻 𝗫-𝗖𝗘𝗟𝗟𝗲𝗿𝗮𝘁𝗼𝗿 2025 – 𝗪𝗵𝗮𝘁 𝗮 𝗗𝗮𝘆! Last week, we welcomed the Cell & Gene Therapy community to the 6th edition of our Open X-CELLerator event in Frankfurt – co-hosted with our trusted partner time:matters.   🔬 We brought together the entire ecosystem – from hospitals and pharma to logistics and tech – to explore how we can collectively shape the future of personalized medicine. 𝗢𝘂𝗿 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 💡  Chris Barkey’s keynote on the current evolution of the CGT industry – from innovation to implementation. 💡 Dr. Dörte Schneider (University Clinic Frankfurt) shared the critical role of hospital pharmacies and the pain points they face in CGT workflows. 💡 Marcel van Houten emphasized the importance of transport validation and the supply chain’s pivotal role in ensuring therapy integrity. 💡 Miriam Flocke, Paul Waltersmann & Cynthia ALPHONSE sparked deep discussions on sustainability in CGT logistics – exploring actionable ideas for greener supply chains. 💡 Gabrielle Silvers opened the floor to traceability and transparency, including the potential of blockchain in CGT logistics. 💡 A panel discussion rounded out the day, bringing diverse voices together to tackle shared challenges. 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: ✅ We need industry-wide standards, especially in IT, to enable scalable processes – particularly in hospital settings. ✅ Collaboration across the industry, even among competitors, is essential to expand patient access. ✅ There are multiple pathways to greener logistics – and the time to act is now. 🔥 We wrapped up the day with a rooftop BBQ, great food, and even better conversations. The inspiration and energy were palpable! Thank you to all speakers, partners, and attendees for making this event a true success. Let’s keep building the future of Cell & Gene Therapy – together. #OpenXCELLerator #AdvancedTherapies #SupplyChain #CellAndGeneTherapy

54

1 Kommentar